Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), with a majority being bullish. The average 12-month price target has risen to $28.5, reflecting a positive shift in sentiment. Key analysts have raised their price targets, indicating optimism about the company's future performance.
June 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics has received predominantly bullish ratings from 14 analysts over the past three months. The average 12-month price target has increased to $28.5, indicating a positive outlook. Key analysts have raised their price targets, suggesting optimism about the company's future performance.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating a positive outlook for the stock. Key analysts raising their price targets further supports this sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100